By Michael Erman and Christy Santhosh (Reuters) -Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus vaccine Gardasil in China. However, shares fell nearly 2% after Merck lowered the high end of its revenue forecast for the full year. It now expects revenue of $64.5 billion to $65.0 billion compared with its prior view of $64.3 billion to $65.3 billion. J.P.Morgan analysts called the quarterly beat ...

Core Insights - Biogen's key growth drivers, Leqembi and Skyclarys, faced challenges in Q3, impacting stock performance [1][2] - Despite these challenges, Biogen reported better-than-expected sales and earnings, driven by older multiple sclerosis treatments [4][5] Financial Performance - Biogen reported earnings of $4.81 per share on $2.54 billion in sales, exceeding analyst forecasts of $3.88 and $2.34 billion respectively [4] - Year-over-year, earnings increased by 18% and sales rose by 3%, with a 2% increase in constant currency [4] - Sales of Skyclarys reached $133 million, slightly below expectations, while Leqembi generated $69 million in U.S. sales, also below projections [2][3] Product Performance - Tysabri sales rose 6% to $431.8 million, surpassing forecasts, while Tecfidera sales fell 28% to $168 million but still exceeded projections [5] - Revenue from Spinraza was in line with expectations at $374 million, reflecting a 2% decline [6] Guidance and Outlook - Biogen lowered its adjusted earnings outlook to $14.50 to $15 per share, accounting for a $1.25 per-share negative impact from business development transactions [7] - The company raised its sales outlook, now expecting flat to 1% growth in constant currency for the year [7][8] - The new earnings guidance fell short of analysts' expectations of $15.76 per share, while sales projections align with Biogen's expectations of $9.69 billion [8]

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker. Lilly said Thursday that its top-selling drugs, Mounjaro and Zepbound, brought in more than $10 billion combined during the recently completed third quarter. That made up over half of the drugmaker’s $17.6 billion in total sales. Separately, Danish drugmaker Novo Nordisk announced plans to buy Metsera Inc. in a deal that could be worth up to $9 b ...

Core Insights - Apellis Pharmaceuticals, Inc. reported a revenue of $458.58 million for the quarter ended September 2025, marking a year-over-year increase of 133% [1] - The earnings per share (EPS) for the same period was $1.67, a significant improvement from -$0.46 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of $366.21 million by 25.22%, while the EPS surprise was 62.14% above the consensus estimate of $1.03 [1] Revenue Breakdown - Product revenue, net was $177.76 million, slightly below the nine-analyst average estimate of $178.43 million, reflecting a year-over-year change of 0.7% [4] - Licensing and other revenue reached $280.82 million, significantly surpassing the estimated $126.67 million, representing a year-over-year increase of 1286.2% [4] - Product Revenue from EMPAVELI was $26.83 million, exceeding the average estimate of $22.06 million, with a year-over-year change of 9% [4] - Product Revenue from SYFOVRE was $150.93 million, slightly below the average estimate of $156.55 million, showing a year-over-year decrease of 0.7% [4] Stock Performance - Shares of Apellis Pharmaceuticals have returned +30.1% over the past month, outperforming the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

For the quarter ended September 2025, Amneal Pharmaceuticals (AMRX) reported revenue of $784.51 million, up 11.7% over the same period last year. EPS came in at $0.17, compared to $0.16 in the year-ago quarter.The reported revenue represents a surprise of +1.41% over the Zacks Consensus Estimate of $773.6 million. With the consensus EPS estimate being $0.13, the EPS surprise was +30.77%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations ...

For the quarter ended September 2025, Merck (MRK) reported revenue of $17.28 billion, up 3.7% over the same period last year. EPS came in at $2.58, compared to $1.57 in the year-ago quarter.The reported revenue represents a surprise of +1.24% over the Zacks Consensus Estimate of $17.06 billion. With the consensus EPS estimate being $2.36, the EPS surprise was +9.32%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expecta ...

The S&P 500 slipped 0.2% from its all-time high earlier this week, while the Nasdaq composite lost 0.6%. The Dow Jones Industrial Average, however, gained 199 points, or 0.5%, by mid-morning trade, AP reported.Markets were reacting to comments from US President Donald Trump, who called his meeting with Chinese President Xi Jinping a “12 out of 10” and announced plans to reduce tariffs on Chinese goods. Analysts, however, warned that despite the warm rhetoric, structural trade tensions remain unresolved.“The ...

Analysts on Wall Street project that Amgen (AMGN) will announce quarterly earnings of $5.00 per share in its forthcoming report, representing a decline of 10.4% year over year. Revenues are projected to reach $8.94 billion, increasing 5.2% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.9% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prio ...

Joining us now exclusively on the phone, I'm sorry, I would love to be, but on the phone's good is Eli Liy, chairman, co Dave Ricks. Dave, when I saw you in the at the JP Morgan conference, there were a lot of people who were kind of bummed that you were not able to raise guidance because they thought things were great. This was a remarkable guidance raise.What's it coming from. >> Hey Jim, good morning and good to be with you today. Yeah, well, as you said, we had a super strong quarter in Q3.the the head, ...

Core Insights - Eli Lilly and Co. reported better-than-expected third-quarter earnings, leading to an increase in stock price and an upward revision of its annual forecast [1][8] Financial Performance - Quarterly revenue reached $17.60 billion, a 54% year-over-year increase, surpassing the consensus estimate of $16.02 billion, driven by a 62% increase in volume, partially offset by a 10% decrease due to lower realized prices [2] - Adjusted earnings per share were reported at $7.02, significantly up from $1.18 a year ago, exceeding the consensus of $5.70 [3] - Key Products revenue grew to $11.98 billion in Q3 2025, primarily driven by Mounjaro and Zepbound [2] Product Performance - Mounjaro's revenue increased by 109% to $6.52 billion, with U.S. revenue at $3.55 billion, reflecting a 49% increase [4] - Zepbound revenue surged 184% to $3.57 billion, driven by increased demand [5] - Verzenio revenue rose 7% to $1.47 billion, supported by volume growth [5] Profitability Metrics - Gross profit increased by 57% to $14.59 billion, with a gross margin of 82.9%, up by 1.9 percentage points due to a favorable product mix [5] Future Outlook - The company raised its fiscal year 2025 sales guidance from $60 billion-$62 billion to $63 billion-$63.5 billion, compared to the consensus of $61.65 billion [6] - Adjusted earnings guidance for 2025 was increased from $21.75-$23.00 to $23-$23.70, against a consensus of $22.18 [6] Investment and Expansion Plans - Eli Lilly announced a planned investment of over $1.2 billion to expand and modernize its manufacturing site in Puerto Rico, with construction expected to begin in 2026 [6][7] - The new facility will integrate advanced technologies and expand production capacity for oral solid medicines, including orforglipron, Lilly's first oral weight loss drug [7] - The project is expected to create up to 1,000 construction jobs and 100 high-tech manufacturing positions [8]